Ozempic and Dementia: What a New Science Review Says About GLP-1 Drugs and the Brain
A Science review weighs whether Ozempic, Wegovy and Mounjaro protect the brain. Observational data look promising, but Alzheimer trials were negative. What we know.
A Science review weighs whether Ozempic, Wegovy and Mounjaro protect the brain. Observational data look promising, but Alzheimer trials were negative. What we know.
Lilly's dopamine D1 modulator mevidalen missed its Phase 2 goal in 304 people with Alzheimer's at CTAD 2026. Full results, blood pressure signal and what it means for treatment.
A JAMA study of 728 people shows a new eMTBR-tau blood test can detect advanced Alzheimer's tau tangles about as well as PET scans. Here is what it can and…
Biogen's tau-lowering antisense drug diranersen slowed CDR-SB decline 38% at two years in the Phase 2 CELIA extension, up from 26% at 18 months. Full data, caveats and Phase 3…
AriBio's once-daily AR1001 slowed Alzheimer's decline 31% in patients on no other dementia drugs in the POLARIS-AD Phase 3 trial, but missed in the full population. Data, safety and next…
A Cell study in mice finds the blood-brain barrier imports 92 blood proteins, and that delivery of protective APOA1 fails early in Alzheimer's.